Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Design, Synthesis and Pharmacological Evalution of 1,3,4-Oxadiazole Derivatives as Collapsin Response Mediator Protein 1 (CRMP 1) Inhibitors

Author(s): Ishan I. Panchal*, Roshani Rajput and Ashish D. Patel

Volume 17, Issue 1, 2020

Page: [57 - 67] Pages: 11

DOI: 10.2174/1570163815666181106090708

Price: $65

Abstract

Objective: The series of 2-(4-Phenylamino)-N-(5-((4-nitrophenoxy)methyl) -1,3,4-oxadiazol- 2-yl)aceta-mide (5a-5e) and substituted N-(5-(Phenoxymethyl)-1,3,4-oxadiazol-2-yl)-2- (phenylamino)acetamide (5f-5i) was designed, synthesized and investigated for Collapsin Response Mediator Protein 1 (CRMP 1) inhibitors as small lung cancer.

Design: Design of compounds was determined by literature review and molecular docking studies in iGEMDOCK 2.0.

Materials and Methods: Novel 1, 3, 4 Oxadiazole derivatives were synthesized and characterized by melting point, TLC, IR Spectroscopy, Mass spectroscopy and 1H NMR. In vitro biological evaluation was performed on NCI-H2066 cell line for different concentrations 10-1000μM by telomeric repeat amplification protocol assay. The assay of telomerase in cellular extracts was modified from the PCR-based Telomeric-Repeat Amplification Protocol (TRAP), using the oligonucleotides TS and CX.

Results: Novel substituted 2-(4-Phenylamino)-N-(5-((4-nitrophenoxy)methyl)-1,3,4-oxadiazol-2- yl) acetamide (5a-5e) and substituted N-(5-(Phenoxymethyl)-1,3,4-oxadiazol-2-yl)-2-(phenylamino) acetamide (5f-5i) were synthesized, and characterized using spectral and analytical data. All compounds have shown considerable % inhibition of Cell Growth with respect to Bevacizumab, but compound 5a and 5f were equipotent with respect to activity as compared to standard Bevacizumab.

Conclusion: Amongst the hybrids, p-nitro substituted derivative (5a) and p-chloro substituted (5f) showed the highest activity against human lung cancer cell line NCI-H2066 by TRAP assay.

Keywords: Oxadiazole, NCI-H2066, cell line, TRAP assay, collapsin response mediator protein 1, cancer.

Graphical Abstract

[1]
Steeg PS. Collapsin response mediator protein-1: A lung cancer invasion suppressor gene with nerve. J Natl Cancer Inst 2001; 93(18): 1364-5.
[http://dx.doi.org/10.1093/jnci/93.18.1364] [PMID: 11562379]
[2]
Ajay K, Anjali G, Varsha K, Gunjan S, Vikas M, Sushil K. Syntheses and anticancer evaluation of some novel 3-[5-(4-substituted) phenyl- 1,3,4-oxadiazole-2yl]-2- phenylquinazoline-4(3h)-ones. Int J Pharm Pharm Sci 2012; 4(1): 502-6.
[3]
National Cancer Institute (NCI). United States federal government’s National Institutes of Health Bethesa, MD. Common Cancers Topic 2012; 12: 15-20.
[4]
Micheal B. Cancer with Natural Medicine 2003; 1-3.
[5]
Yoshikawa M. Aryl Hydrocarbon hydroxylase activity in human lung cancer. Environ Res 1994; 65: 1-11.
[http://dx.doi.org/10.1006/enrs.1994.1017] [PMID: 8162876]
[6]
Biju CR, Ilango K. Docking investigation, synthesis and cytotoxic studies of substituted oxadiazole derivatives. Int J Pharm Pharm Sci 2012; 4(3): 262-5.
[7]
Bereket M. Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents. Bioorg Med Chem 2016; 26: 2487-851.
[8]
Bhargab N. Synthesis and characterization of some novel oxadiazoles for in vitro anti-inflammatory. Int J Res Pharm Chem 2012; 2: 594-602.
[9]
Arora P, Narang R, Bhatia S, Nayak SK, Singh SK, Narasimhan B. Synthesis, molecular docking and QSAR studies of 2, 4- disubstituted thiazoles as antimicrobial agents. J Appl Pharm Sci 2015; 5(02): 28-42.
[http://dx.doi.org/10.7324/JAPS.2015.50206]
[10]
Sharma PK, Chandak N, Kumar P, Sharma C, Aneja KR. Synthesis and biological evaluation of some 4-functionalized-pyrazoles as antimicrobial agents. Eur J Med Chem 2011; 46(4): 1425-32.
[http://dx.doi.org/10.1016/j.ejmech.2011.01.060] [PMID: 21342734]
[11]
Padmavathi V, Sudhakar Reddy G, Padmaja A, Kondaiah P, Ali-Shazia . Synthesis, antimicrobial and cytotoxic activities of 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazoles. Eur J Med Chem 2009; 44(5): 2106-12.
[http://dx.doi.org/10.1016/j.ejmech.2008.10.012] [PMID: 19036476]
[12]
El-Emam AA, Al-Deeb OA, Al-Omar M, Lehmann J. Synthesis, antimicrobial, and anti-HIV-1 activity of certain 5-(1-adamantyl)-2-substituted thio-1,3,4-oxadiazoles and 5-(1-adamantyl)-3-substituted aminomethyl-1,3,4-oxadiazoline-2-thiones. Bioorg Med Chem 2004; 12(19): 5107-13.
[http://dx.doi.org/10.1016/j.bmc.2004.07.033] [PMID: 15351394]
[13]
Al-Saadi S, Rostom A, Faidallah M. In vitro antitumor screening of some polysubstituted pyrazole analogs. Saudi Pharm J 2005; 13: 88-96.
[14]
Qian X, Li Z, Yang Q. Highly efficient antitumor agents of heterocycles containing sulfur atom: linear and angular thiazonaphthalimides against human lung cancer cell in vitro. Bioorg Med Chem 2007; 15(21): 6846-51.
[http://dx.doi.org/10.1016/j.bmc.2007.07.008] [PMID: 17707644]
[15]
Aboraia AS, Abdel-Rahman HM, Mahfouz NM, El-Gendy MA. Novel 5-(2-hydroxyphenyl)-3-substituted-2,3-dihydro-1,3,4-oxadiazole-2-thione derivatives: promising anticancer agents. Bioorg Med Chem 2006; 14(4): 1236-46.
[http://dx.doi.org/10.1016/j.bmc.2005.09.053] [PMID: 16242340]
[16]
Li Z, Zhan P, Liu X. 1,3,4-oxadiazole: a privileged structure in antiviral agents. Mini Rev Med Chem 2011; 11(13): 1130-42.
[http://dx.doi.org/10.2174/138955711797655407] [PMID: 22353222]
[17]
Riyadh SM, Farghaly TA, Abdallah MA, Abdalla MM, Abd El-Aziz MR. New pyrazoles incorporating pyrazolylpyrazole moiety: synthesis, anti-HCV and antitumor activity. Eur J Med Chem 2010; 45(3): 1042-50.
[http://dx.doi.org/10.1016/j.ejmech.2009.11.050] [PMID: 20022411]
[18]
El-Sayed A, El-Essawy A, Ali M, Nasr S, Abdalla M, Abdel-Rahman A. A Synthesis and antiviral evaluation of new 2,5- disubstituted 1,3,4-oxadiazole derivatives and their acyclic nucleoside analogues. Monatsh Chem 2010; 141: 1021-8.
[http://dx.doi.org/10.1007/s00706-010-0360-y]
[19]
Srivastava PC, Pickering MV, Allen LB, et al. Synthesis and antiviral activity of certain thiazole C-nucleosides. J Med Chem 1977; 20(2): 256-62.
[http://dx.doi.org/10.1021/jm00212a014] [PMID: 189032]
[20]
Salahuddin M, Mazumder A, Shaharyar M. Synthesis, characterization, and in vitro anticancer evaluation of novel 2,5-disubstituted 1,3,4-oxadiazole analogue. BioMed Res Int 2014; 2014491492
[http://dx.doi.org/10.1155/2014/491492] [PMID: 25177693]
[21]
Ahsan MJ, Sharma J, Singh M, Jadav SS, Yasmin S. Synthesis and anticancer activity of N-aryl-5-substituted-1,3,4-oxadiazol-2-amine analogues. BioMed Res Int 2014; 2014814984
[http://dx.doi.org/10.1155/2014/814984] [PMID: 24977160]
[22]
Mohamed A, Sunil S, Rita Y, et al. Synthesis and antiproliferative activity of some quinoline and oxadiazole derivatives. Org Chem Int 2016; 9589517: 1-10.
[23]
Gamal El-Din MM, El-Gamal MI, Abdel-Maksoud MS, Yoo KH, Oh CH, Kyung Y. Synthesis and in vitro antiproliferative activity of new 1,3,4-oxadiazole derivatives possessing sulfonamide moiety. Eur J Med Chem 2015; 90: 45-52.
[http://dx.doi.org/10.1016/j.ejmech.2014.11.011] [PMID: 25461310]
[24]
Liu SH, Huang SF, Hsu YL, Pan SH, Chen YJ, Lin YH. Structure of human collapsin response mediator protein 1: a possible role of its C-terminal tail. Acta Crystallogr F Struct Biol Commun 2015; 71(Pt 8): 938-45.
[http://dx.doi.org/10.1107/S2053230X15009243] [PMID: 26249678]
[25]
Ishan IP, Ashish S, Animesh D, et al. In silico analysis and molecular docking studies of novel 6,7-dihydropyrano [2,3-d] pyrimidin-5-one derivatives as Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor (EGFR) inhibitors. Curr Cancer Ther Rev 2019; 15: 1-13.
[26]
Panchal II, Badeliya SN, Patel R. In silico analysis and molecular docking studies of novel 4-Amino-3-(isoquinolin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine derivatives as Dual PI3K/mTOR inhibitors. Curr Drug Discov Technol 2018; 15: 1.

Rights & Permissions Print Cite
Article Metrics
10
1
© 2024 Bentham Science Publishers | Privacy Policy